Dementia Trials

In this single-center phase-II pilot RCT of 42 completers, nicotinamide riboside safely doubled blood NAD+ but did not improve cognitive function, total cerebral blood flow, blood pressure, or arteria...

In two large phase 3 trials totalling 3808 amyloid-positive early Alzheimer's disease participants, oral semaglutide up to 14 mg once daily did NOT slow CDR-SB progression versus placebo at week 104, ...

Liraglutide 1.8 mg SC daily for 52 weeks did NOT reduce decline in cerebral glucose metabolism (primary outcome) in mild-to-moderate Alzheimer's disease, but showed an exploratory cognitive benefit on...

Can crenezumab, started before symptom onset, prevent or delay cognitive decline in cognitively unimpaired PSEN1 Glu280Ala mutation carriers predestined to develop autosomal-dominant Alzheimer's disease?

Does low-dose lithium slow cognitive decline and preserve brain volume in adults with mild cognitive impairment?

Can longitudinal changes in plasma p-tau217 serve as a primary endpoint for early AD clinical trials, and what sample sizes/costs does that imply?

Can plasma %p-tau217 clock models predict the age at onset of symptomatic Alzheimer disease in cognitively unimpaired individuals?

Plasma p-tau217 Clocks for Predicting Onset of Alzheimer Disease

Can a tau aggregation inhibitor slow cognitive decline in MCI and mild-to-moderate Alzheimer disease?

Hydromethylthionine Mesylate (HMTM) for MCI and Mild-to-Moderate Alzheimer Disease

Can plasma %p-tau217 clock models estimate the age at biomarker positivity and predict when cognitively unimpaired individuals will develop symptomatic Alzheimer disease?

Does the fully automated Lumipulse plasma p-tau217 immunoassay accurately detect Alzheimer disease pathology in symptomatic patients across diverse clinical settings using predefined biomarker cutoffs?